Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    bms906024
Show Display Options
Rank Status Study
1 Recruiting Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
Condition: Cancer
Intervention: Drug: BMS-906024
2 Recruiting Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
Condition: Cancer
Interventions: Drug: Paclitaxel;   Drug: 5-Fluorouracil (5FU);   Drug: Carboplatin;   Drug: Leucovorin;   Drug: Irinotecan;   Drug: BMS-906024
3 Recruiting Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions: Lymphoblastic Leukemia, Acute T-cell;   Precursor T-Cell Lymphoblastic Lymphoma
Interventions: Drug: BMS-906024;   Drug: Dexamethasone

Indicates status has not been verified in more than two years